Puma Biotechnology/PBYI

$5.17

1.37%
-
1D1W1MYTD1YMAX

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Ticker

PBYI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alan Auerbach

Employees

185

Headquarters

Los angeles, United States

PBYI Metrics

BasicAdvanced
$257.91M
Market cap
11.85
P/E ratio
$0.45
EPS
1.28
Beta
-
Dividend rate
$257.91M
1.28471
$7.73
$2.13
611.74K
1.572
1.5
122.86
186.475
12.781
3.1%
9.54%
57.54%
15.66%
11.85
1.095
4.77
17.949
3.34%
10,698.12%
1.54%

What the Analysts think about PBYI

Analyst Ratings

Majority rating from 3 analysts.
Hold

Price Targets

Average projection from 3 analysts.
16.25% downside
High $7.00
Low $2.00
$5.17
Current price
$4.33
Average price target

PBYI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
16.92% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$72.1M
28.52%
Net income
$12.2M
114.04%
Profit margin
16.92%
66.54%

PBYI Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 13.24%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.03
$0.05
$0.12
$0.26
-
Expected
-$0.07
$0.01
$0.08
$0.30
-$0.22
Surprise
-142.86%
566.67%
56.52%
-13.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Puma Biotechnology stock?

Puma Biotechnology (PBYI) has a market cap of $257.91M as of April 17, 2024.

What is the P/E ratio for Puma Biotechnology stock?

The price to earnings (P/E) ratio for Puma Biotechnology (PBYI) stock is 11.85 as of April 17, 2024.

Does Puma Biotechnology stock pay dividends?

No, Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Puma Biotechnology dividend payment date?

Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders.

What is the beta indicator for Puma Biotechnology?

Puma Biotechnology (PBYI) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Puma Biotechnology stock price target?

The target price for Puma Biotechnology (PBYI) stock is $4.33, which is 16.25% below the current price of $5.17. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Puma Biotechnology stock

Buy or sell Puma Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing